Givaudan
This article was originally published in The Rose Sheet
Executive Summary
Sales of the fine fragrance unit fell 1.9% to $224.9 mil. (CHF1=$.82) during the first quarter of 2005, hampered by "strong comparables, particularly in the specialty retail segment and several postponed launches," Givaudan announces. North American sales of the division were sluggish compared to last year, the company adds. Net sales in the quarter declined 4.7% to $550.6 mil., due in part to the streamlining of non-core ingredients, according to firm...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.